174 related articles for article (PubMed ID: 16772043)
1. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
He H; Wisner P; Yang G; Hu HM; Haley D; Miller W; O'Hara A; Alvord WG; Clegg CH; Fox BA; Urba WJ; Walker EB
J Transl Med; 2006 Jun; 4():24. PubMed ID: 16772043
[TBL] [Abstract][Full Text] [Related]
2. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
[TBL] [Abstract][Full Text] [Related]
4. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
5. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
6. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
9. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
[TBL] [Abstract][Full Text] [Related]
12. Adoptive CD8
Fu J; Yu A; Tang J; He B; Chen W
Am J Transl Res; 2020; 12(11):7262-7274. PubMed ID: 33312365
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
[TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model.
Nawrath M; Pavlovic J; Moelling K
J Mol Med (Berl); 2001 Apr; 79(2-3):133-42. PubMed ID: 11357937
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of augmented anti-tumor immunity in reconstituted lymphopenic mice immunized with melanoma vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):708-12. PubMed ID: 16483476
[TBL] [Abstract][Full Text] [Related]
20. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
Gordy JT; Luo K; Zhang H; Biragyn A; Markham RB
J Immunother Cancer; 2016; 4():96. PubMed ID: 28018602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]